(MedPage Today) -- Long-term immunosuppressive treatment with adalimumab (Humira) was associated with low rates of adverse events such as serious infections and malignancies, researchers reported. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment